Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)

Patrick Y. Wen; Timothy F. Cloughesy; Benjamin M. Ellingson; David A. Reardon; Howard A. Fine; Lauren Abrey; Karla Ballman; Martin Bendszuz; Jan Buckner; Susan M. Chang; Michael D. Prados; Whitney B. Pope; Alma Gregory Sorensen; Martin Van Den Bent; Wai Kwan Alfred Yung

doi:10.1093/neuonc/nou226

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)

Patrick Y. Wen, Timothy F. Cloughesy, Benjamin M. Ellingson, David A. Reardon, Howard A. Fine, Lauren Abrey, Karla Ballman, Martin Bendszuz, Jan Buckner, Susan M. Chang, Michael D. Prados, Whitney B. Pope, Alma Gregory Sorensen, Martin Van Den Bent, Wai Kwan Alfred Yung

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

On January 30, 2014, a workshop was held on neuroimaging endpoints in high-grade glioma. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, Accelerate Brain Cancer Cure, and the Musella Foundation for Research and Information, and conducted in collaboration with the Food and Drug Administration. The workshop included neuro-oncologists, neuroradiologists, radiation oncologists, neurosurgeons, biostatisticians, patient advocates, and representatives from industry, clinical research organizations, and the National Cancer Institute. This report summarizes the presentations and discussions of that workshop and the proposals that emerged to improve the Response Assessment in Neuro-Oncology (RANO) criteria and standardize neuroimaging parameters.

Original language	English (US)
Pages (from-to)	vii36-vii47
Journal	Neuro-oncology
Volume	16
DOIs	https://doi.org/10.1093/neuonc/nou226
State	Published - Oct 1 2014

Keywords

Brain tumor
Endpoints
Neuroimaging
RANO
Workshop.

ASJC Scopus subject areas

Oncology
Clinical Neurology
Cancer Research

Access to Document

10.1093/neuonc/nou226

Cite this

Wen, P. Y., Cloughesy, T. F., Ellingson, B. M., Reardon, D. A., Fine, H. A., Abrey, L., Ballman, K., Bendszuz, M., Buckner, J., Chang, S. M., Prados, M. D., Pope, W. B., Sorensen, A. G., Van Den Bent, M., & Yung, W. K. A. (2014). Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro-oncology, 16, vii36-vii47. https://doi.org/10.1093/neuonc/nou226

Wen, PY, Cloughesy, TF, Ellingson, BM, Reardon, DA, Fine, HA, Abrey, L, Ballman, K, Bendszuz, M, Buckner, J, Chang, SM, Prados, MD, Pope, WB, Sorensen, AG, Van Den Bent, M & Yung, WKA 2014, 'Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)', Neuro-oncology, vol. 16, pp. vii36-vii47. https://doi.org/10.1093/neuonc/nou226

@article{150503aacf8447589ff92ecfbb40b571,

title = "Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)",

abstract = "On January 30, 2014, a workshop was held on neuroimaging endpoints in high-grade glioma. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, Accelerate Brain Cancer Cure, and the Musella Foundation for Research and Information, and conducted in collaboration with the Food and Drug Administration. The workshop included neuro-oncologists, neuroradiologists, radiation oncologists, neurosurgeons, biostatisticians, patient advocates, and representatives from industry, clinical research organizations, and the National Cancer Institute. This report summarizes the presentations and discussions of that workshop and the proposals that emerged to improve the Response Assessment in Neuro-Oncology (RANO) criteria and standardize neuroimaging parameters.",

keywords = "Brain tumor, Endpoints, Neuroimaging, RANO, Workshop.",

author = "Wen, {Patrick Y.} and Cloughesy, {Timothy F.} and Ellingson, {Benjamin M.} and Reardon, {David A.} and Fine, {Howard A.} and Lauren Abrey and Karla Ballman and Martin Bendszuz and Jan Buckner and Chang, {Susan M.} and Prados, {Michael D.} and Pope, {Whitney B.} and Sorensen, {Alma Gregory} and {Van Den Bent}, Martin and Yung, {Wai Kwan Alfred}",

year = "2014",

month = oct,

day = "1",

doi = "10.1093/neuonc/nou226",

language = "English (US)",

volume = "16",

pages = "vii36--vii47",

journal = "Neuro-oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)

AU - Wen, Patrick Y.

AU - Cloughesy, Timothy F.

AU - Ellingson, Benjamin M.

AU - Reardon, David A.

AU - Fine, Howard A.

AU - Abrey, Lauren

AU - Ballman, Karla

AU - Bendszuz, Martin

AU - Buckner, Jan

AU - Chang, Susan M.

AU - Prados, Michael D.

AU - Pope, Whitney B.

AU - Sorensen, Alma Gregory

AU - Van Den Bent, Martin

AU - Yung, Wai Kwan Alfred

PY - 2014/10/1

Y1 - 2014/10/1

N2 - On January 30, 2014, a workshop was held on neuroimaging endpoints in high-grade glioma. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, Accelerate Brain Cancer Cure, and the Musella Foundation for Research and Information, and conducted in collaboration with the Food and Drug Administration. The workshop included neuro-oncologists, neuroradiologists, radiation oncologists, neurosurgeons, biostatisticians, patient advocates, and representatives from industry, clinical research organizations, and the National Cancer Institute. This report summarizes the presentations and discussions of that workshop and the proposals that emerged to improve the Response Assessment in Neuro-Oncology (RANO) criteria and standardize neuroimaging parameters.

AB - On January 30, 2014, a workshop was held on neuroimaging endpoints in high-grade glioma. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, Accelerate Brain Cancer Cure, and the Musella Foundation for Research and Information, and conducted in collaboration with the Food and Drug Administration. The workshop included neuro-oncologists, neuroradiologists, radiation oncologists, neurosurgeons, biostatisticians, patient advocates, and representatives from industry, clinical research organizations, and the National Cancer Institute. This report summarizes the presentations and discussions of that workshop and the proposals that emerged to improve the Response Assessment in Neuro-Oncology (RANO) criteria and standardize neuroimaging parameters.

KW - Brain tumor

KW - Endpoints

KW - Neuroimaging

KW - RANO

KW - Workshop.

UR - http://www.scopus.com/inward/record.url?scp=84965187416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965187416&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nou226

DO - 10.1093/neuonc/nou226

M3 - Article

C2 - 25313237

AN - SCOPUS:84965187416

SN - 1522-8517

VL - 16

SP - vii36-vii47

JO - Neuro-oncology

JF - Neuro-oncology

ER -

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this